PDS Planning Inc Has $3.94 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

PDS Planning Inc grew its holdings in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 1.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,065 shares of the company’s stock after buying an additional 81 shares during the quarter. PDS Planning Inc’s holdings in Eli Lilly and Company were worth $3,940,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Hanlon Investment Management Inc. raised its position in Eli Lilly and Company by 3.3% in the first quarter. Hanlon Investment Management Inc. now owns 3,534 shares of the company’s stock worth $2,749,000 after acquiring an additional 112 shares during the period. Westwood Wealth Management bought a new stake in Eli Lilly and Company in the first quarter worth about $1,256,000. Paces Ferry Wealth Advisors LLC bought a new stake in Eli Lilly and Company in the first quarter worth about $312,000. Resonant Capital Advisors LLC raised its position in Eli Lilly and Company by 16.2% in the first quarter. Resonant Capital Advisors LLC now owns 5,359 shares of the company’s stock worth $4,169,000 after acquiring an additional 747 shares during the period. Finally, Blackhawk Capital Partners LLC. raised its position in Eli Lilly and Company by 0.4% in the first quarter. Blackhawk Capital Partners LLC. now owns 4,880 shares of the company’s stock worth $3,796,000 after acquiring an additional 20 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $914.57 on Monday. Eli Lilly and Company has a 52-week low of $434.34 and a 52-week high of $918.50. The stock has a market capitalization of $869.22 billion, a price-to-earnings ratio of 134.69, a price-to-earnings-growth ratio of 1.99 and a beta of 0.41. The company has a fifty day moving average of $831.69 and a 200-day moving average of $752.53. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the prior year, the company earned $1.62 EPS. The firm’s revenue was up 26.0% on a year-over-year basis. Equities research analysts expect that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.57%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Analyst Ratings Changes

LLY has been the topic of several research reports. Truist Financial reaffirmed a “buy” rating and issued a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Bank of America reissued a “buy” rating and issued a $1,000.00 price target on shares of Eli Lilly and Company in a research report on Monday, June 24th. Citigroup boosted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Jefferies Financial Group boosted their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Finally, Argus upped their target price on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a report on Tuesday, May 14th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $816.78.

View Our Latest Stock Report on LLY

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the sale, the insider now directly owns 98,554,195 shares in the company, valued at approximately $79,730,343,755. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the transaction, the insider now owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The disclosure for this sale can be found here. Insiders sold 858,742 shares of company stock worth $735,573,781 in the last three months. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Articles

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.